Business Description

Aligos Therapeutics Inc
NAICS : 541714
SIC : 2834
Compare
Compare
Traded in other countries / regions
5WK.GermanyALGS.USA IPO Date
2020-10-16Description
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 10.01 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.13 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -4.37 | |||||
Beneish M-Score | -1.44 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 2.3 | |||||
3-Year EPS without NRI Growth Rate | 3.1 | |||||
3-Year FCF Growth Rate | 5.9 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 8.83 | |||||
9-Day RSI | 17.61 | |||||
14-Day RSI | 26.68 | |||||
6-1 Month Momentum % | 47.17 | |||||
12-1 Month Momentum % | -33.9 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.03 | |||||
Quick Ratio | 4.03 | |||||
Cash Ratio | 3.8 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -25.1 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -701.66 | |||||
Net Margin % | -690.63 | |||||
ROE % | -68.55 | |||||
ROA % | -51.14 | |||||
ROIC % | -264.38 | |||||
ROC (Joel Greenblatt) % | -698.94 | |||||
ROCE % | -63.9 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 3.47 | |||||
PB Ratio | 0.47 | |||||
Price-to-Tangible-Book | 0.47 | |||||
EV-to-EBIT | 0.66 | |||||
EV-to-EBITDA | 0.69 | |||||
EV-to-Revenue | -4.65 | |||||
EV-to-FCF | 0.81 | |||||
Price-to-Net-Current-Asset-Value | 0.54 | |||||
Price-to-Net-Cash | 0.59 | |||||
Earnings Yield (Greenblatt) % | 151.52 |
How Aligos Therapeutics Inc (ALGS) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALGS
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 13.907 | ||
EPS (TTM) ($) | -2.26 | ||
Beta | 0 | ||
Volatility % | 122.89 | ||
14-Day RSI | 26.68 | ||
14-Day ATR ($) | 0.138421 | ||
20-Day SMA ($) | 1.35775 | ||
12-1 Month Momentum % | -33.9 | ||
52-Week Range ($) | 0.8401 - 2.46 | ||
Shares Outstanding (Mil) | 42.94 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Aligos Therapeutics Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |
Aligos Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Aligos Therapeutics Inc Frequently Asked Questions
What is Aligos Therapeutics Inc(ALGS)'s stock price today?
The current price of ALGS is $1.13. The 52 week high of ALGS is $2.46 and 52 week low is $0.84.
When is next earnings date of Aligos Therapeutics Inc(ALGS)?
The next earnings date of Aligos Therapeutics Inc(ALGS) is 2023-05-04 Est..
Does Aligos Therapeutics Inc(ALGS) pay dividends? If so, how much?
Aligos Therapeutics Inc(ALGS) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |